Amundi Has $12.31 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Amundi cut its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 12.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 572,912 shares of the company's stock after selling 80,958 shares during the quarter. Amundi owned 0.05% of Teva Pharmaceutical Industries worth $12,312,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. FMR LLC boosted its position in Teva Pharmaceutical Industries by 49.5% during the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company's stock worth $1,130,589,000 after acquiring an additional 20,762,226 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Lingotto Investment Management LLP raised its stake in shares of Teva Pharmaceutical Industries by 2.6% during the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock worth $599,320,000 after purchasing an additional 688,862 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock worth $573,822,000 after purchasing an additional 569,412 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company's stock worth $351,402,000 after purchasing an additional 1,778,268 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded down $0.09 on Friday, reaching $16.38. 6,488,903 shares of the company were exchanged, compared to its average volume of 12,964,806. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The stock's fifty day moving average price is $18.28 and its 200 day moving average price is $18.29. The firm has a market capitalization of $18.57 billion, a PE ratio of -11.29, a PEG ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Friday, March 7th. Bank of America cut their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Finally, Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.